WO2008038146A2 - Improved processes for preparing vanlafaxine base and salts thereof - Google Patents
Improved processes for preparing vanlafaxine base and salts thereof Download PDFInfo
- Publication number
- WO2008038146A2 WO2008038146A2 PCT/IB2007/003757 IB2007003757W WO2008038146A2 WO 2008038146 A2 WO2008038146 A2 WO 2008038146A2 IB 2007003757 W IB2007003757 W IB 2007003757W WO 2008038146 A2 WO2008038146 A2 WO 2008038146A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- approximately
- venlafaxine
- pharmaceutically acceptable
- solvates
- hydrates
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 32
- 150000003839 salts Chemical class 0.000 title claims abstract description 32
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims abstract description 63
- 229960004688 venlafaxine Drugs 0.000 claims abstract description 60
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 65
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 48
- 239000002245 particle Substances 0.000 claims description 37
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 36
- 239000012535 impurity Substances 0.000 claims description 33
- QYRYFNHXARDNFZ-UHFFFAOYSA-N venlafaxine hydrochloride Chemical group [H+].[Cl-].C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 QYRYFNHXARDNFZ-UHFFFAOYSA-N 0.000 claims description 31
- 229960002416 venlafaxine hydrochloride Drugs 0.000 claims description 29
- 150000004677 hydrates Chemical class 0.000 claims description 19
- 239000012453 solvate Substances 0.000 claims description 19
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 18
- 235000019253 formic acid Nutrition 0.000 claims description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 15
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 238000004817 gas chromatography Methods 0.000 claims description 8
- 238000004007 reversed phase HPLC Methods 0.000 claims description 8
- NTKXIDDUCSFBBF-UHFFFAOYSA-N 1-[2-amino-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C(CN)C1(O)CCCCC1 NTKXIDDUCSFBBF-UHFFFAOYSA-N 0.000 claims description 7
- SUQHIQRIIBKNOR-UHFFFAOYSA-N N,N-didesmethylvenlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN)C1(O)CCCCC1 SUQHIQRIIBKNOR-UHFFFAOYSA-N 0.000 claims description 7
- 238000009826 distribution Methods 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 229940093499 ethyl acetate Drugs 0.000 description 19
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 229910001868 water Inorganic materials 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000001307 helium Substances 0.000 description 3
- 229910052734 helium Inorganic materials 0.000 description 3
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- -1 N,N-dimethylaminomethyl group Chemical group 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 229910019670 (NH4)H2PO4 Inorganic materials 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- HPXRVTGHNJAIIH-PTQBSOBMSA-N cyclohexanol Chemical group O[13CH]1CCCCC1 HPXRVTGHNJAIIH-PTQBSOBMSA-N 0.000 description 1
- HFNCOTSLOKKPHU-UHFFFAOYSA-N cyclohexanol;hydrochloride Chemical compound Cl.OC1CCCCC1 HFNCOTSLOKKPHU-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940098766 effexor Drugs 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000001507 sample dispersion Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- MECFLMNXIXDIOF-UHFFFAOYSA-L zinc;dibutoxy-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [Zn+2].CCCCOP([S-])(=S)OCCCC.CCCCOP([S-])(=S)OCCCC MECFLMNXIXDIOF-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002657912A CA2657912A1 (en) | 2006-07-14 | 2007-07-13 | Improved processes for preparing venlafaxine base and salts thereof |
EP07858939A EP2081885A2 (en) | 2006-07-14 | 2007-07-13 | Improved processes for preparing venlafaxine base and salts thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83061606P | 2006-07-14 | 2006-07-14 | |
US60/830,616 | 2006-07-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008038146A2 true WO2008038146A2 (en) | 2008-04-03 |
WO2008038146A3 WO2008038146A3 (en) | 2008-11-13 |
Family
ID=39230603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2007/003757 WO2008038146A2 (en) | 2006-07-14 | 2007-07-13 | Improved processes for preparing vanlafaxine base and salts thereof |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2081885A2 (en) |
AR (1) | AR062064A1 (en) |
CA (1) | CA2657912A1 (en) |
WO (1) | WO2008038146A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002045658A2 (en) * | 2000-10-19 | 2002-06-13 | Teva Pharmaceutical Industries Ltd. | Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof |
WO2003050074A1 (en) * | 2001-12-13 | 2003-06-19 | Cadila Healthcare Limited | Manufacture of venlafaxine hydrochloride and crystalline polymorphs thereof |
EP1466889A1 (en) * | 1999-04-06 | 2004-10-13 | Sepracor Inc. | Derivatives of venlafaxine and methods of preparing and using the same |
-
2007
- 2007-07-13 EP EP07858939A patent/EP2081885A2/en not_active Withdrawn
- 2007-07-13 CA CA002657912A patent/CA2657912A1/en not_active Abandoned
- 2007-07-13 AR ARP070103131A patent/AR062064A1/en unknown
- 2007-07-13 WO PCT/IB2007/003757 patent/WO2008038146A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1466889A1 (en) * | 1999-04-06 | 2004-10-13 | Sepracor Inc. | Derivatives of venlafaxine and methods of preparing and using the same |
WO2002045658A2 (en) * | 2000-10-19 | 2002-06-13 | Teva Pharmaceutical Industries Ltd. | Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof |
WO2003050074A1 (en) * | 2001-12-13 | 2003-06-19 | Cadila Healthcare Limited | Manufacture of venlafaxine hydrochloride and crystalline polymorphs thereof |
Non-Patent Citations (1)
Title |
---|
YARDLEY J P ET AL: "2-PHENYL-2-(1-HYDROXYCYCLOALKYL)ETHYLAMIN E DERIVATIVES: SYNTHESIS AND ANTIDEPRESSANT ACTIVITY" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 33, 1990, pages 2899-2905, XP000891765 ISSN: 0022-2623 * |
Also Published As
Publication number | Publication date |
---|---|
CA2657912A1 (en) | 2008-04-03 |
EP2081885A2 (en) | 2009-07-29 |
AR062064A1 (en) | 2008-10-15 |
WO2008038146A3 (en) | 2008-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1360169B1 (en) | Succinate salt of o-desmethyl-venlafaxine | |
EP1761478B1 (en) | An isolated atomoxetine impurity, processes for the preparation of atomoxetine impurities and their use as reference standards | |
AU2002250058A1 (en) | Novel succinate salt of O-desmethyl-venlafaxine | |
KR20070088485A (en) | Purification of cinacalcet | |
EP2896609A1 (en) | Crystalline fingolimod citrate for the treatment of relapsing-remitting multiple sclerosis | |
US20100121108A1 (en) | Process for synthesizing desvenlafaxine free base and salts or solvates thereof | |
US6245917B1 (en) | Crystalline sodium phenytoin monohydrate | |
TWI492919B (en) | Process for the production of ralfinamide salts substantially free from impurities having genotoxic effects | |
WO2008038146A2 (en) | Improved processes for preparing vanlafaxine base and salts thereof | |
WO2011095985A2 (en) | Rasagiline salts and processes for the preparation thereof | |
EP3772510B1 (en) | Process for preparing safinamide | |
CN105431409A (en) | Process for preparation of arformoterol of salt thereof | |
EP2213647A1 (en) | Novel crystalline forms of atovaquone | |
CN113024405A (en) | Novel lacosamide impurity and preparation method and application thereof | |
CN112374999A (en) | Preparation method of impurity compound for defluorination of cinacalcet hydrochloride | |
CA2717580A1 (en) | Processes for the preparation of o-desmethylvenlafaxine, free from its dimer impurities | |
AU2007203410A1 (en) | Novel succinate salt of o-desmethyl-venlafaxine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2657912 Country of ref document: CA |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 848/CHENP/2009 Country of ref document: IN Ref document number: 2007858939 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: RU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07858939 Country of ref document: EP Kind code of ref document: A2 |